ESR1 and ovarian cancer: The growth response of ovarian cancer cells to tamoxifen and pure anti-estrogens such as fulvestrant (faslodex; ICI 182,780) has been evaluated in ERα-high- and ERα-low-expressing ovarian cancer cell lines [32,33,34].